Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability
- 498 Downloads
2,5-Dimethoxyphenethylamines and their N-benzylated derivatives are potent 5-HT2A agonists with psychedelic effects in humans. The N-benzylated derivatives are among the most selective 5-HT2A agonists currently available and their usage as biochemical and brain imaging tools is increasing, yet very little is known about the relationships between the structure of the ligands and their pharmacokinetic profile. In order to evaluate the potential of these compounds for in vivo applications we have determined the microsomal stability of 11 phenethylamines and 27 N-benzylated derivatives thereof using human liver microsomes. We found that the N-benzylated phenethylamines have much higher intrinsic clearance than the parent phenethylamines. We hypothesize that their low hepatic stability renders them orally inactive due to first pass metabolism, which is supported by anecdotal data from recreational use of these compounds.
KeywordsPhenethylamines N-benzylphenethylamines Microsomal stability 5-HT2A agonists Psychedelics
Conflict of interest
The authors declare no conflict of interest associated with the present study.
- 1.Schultes RE, Hofmann A (1979) Plants of the gods: origins of hallucinogenic use. Alfred van der Marck Editions, New YorkGoogle Scholar
- 3.UNODC, World Drug Report (2013) United Nations publication, Sales no. E.13.XI.6Google Scholar
- 11.Coyle JR, Presti DE, Baggott MJ (2012) Quantitative analysis of narrative reports of psychedelic drugs. arXiv:1206.0312v1Google Scholar
- 13.Holmstedt B, Liljestrand G (1963) (eds) Readings in pharmacology. Macmillan, New YorkGoogle Scholar
- 15.Juncosa JI Jr, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE (2013) Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chem Neurosci 4(1):96–109PubMedCrossRefPubMedCentralGoogle Scholar
- 17.Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, Lehel S, Herth MM, Madsen J, Kristensen J, Begtrup M, Knudsen GM (2011) Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging 38(4):681–693PubMedCrossRefGoogle Scholar
- 23.Shulgin A, Shulgin A (1991) PIHKAL: a chemical love story. Transform Press, BerkeleyGoogle Scholar
- 24.Carmo H, Hengstler JG, de Boer D, Ringel M, Remião F, Carvalho F, Fernandes E, dos Reys LA, Oesch F, de Bastos LM (2005) Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 206(1):75–89PubMedCrossRefGoogle Scholar
- 28.Theobald DS, Maurer HH (2006) Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J Chromatogr B Anal Technol Biomed Life Sci 842(2):76–90CrossRefGoogle Scholar
- 34.Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott Williams & Wilkins, MediaGoogle Scholar